Professional Documents
Culture Documents
7
6
6
Fig. 6. Effects of PPAR ligands on IFN-g-induced CD40 expression on human endothelial cells. Flow cytometry analysis for CD40 expression. Human vascular endothelial cells (ECs) treated with
IFN-g (500 U/ ml, 24 h) alone (green line), or with the PPAR-g ligands (red lines) 15d-PGJ (10 mmol / l) (A), Troglitazone (50 mmol / l) (B); or with the PPAR-a ligands (red lines) ETYA (50 mmol / l)
2
(C), and WY14643 (50 mmol / l) (D). Each panel is a histogram representing cell numbers ( y-axis) vs. log uorescence intensity (x-axis) for 15,000 viable cells, and ECs under unstimulated conditions
are shown (solid histograms) as well as isotype controls (dotted lines). Similar results were obtained in independent experiments with ECs from ve different donors.
b y g u e s t o n A p r i l 2 5 , 2 0 1 4h t t p : / / c a r d i o v a s c r e s . o x f o r d j o u r n a l s . o r g /D o w n l o a d e d f r o m
F. Mulhaupt et al. / Cardiovascular Research 59 (2003) 755766 765
is expressed on human vascular endothelial cells, smooth muscle
matosus, autoimmune diabetes mellitus, chronic arthritis
cells, and macrophages: implications for CD40CD40 ligand sig-
and graft-versus-host disease.
naling in atherosclerosis. Proc Natl Acad Sci USA 1997;94:1931
1936.
[19] Wiszniewski L, Limat A, Saurat JH, Meda P, Salomon D. Differen-
Acknowledgements tial expression of connexins during stratication of human keratino-
cytes. J Invest Dermatol 2000;115:278285.
[20] Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock
The authors thank Dr Ludovic Wiszniewski (Department
protein 60 localizes in human atheroma and regulates macrophage
of Pediatrics, Geneva University Hospital) for providing us
tumor necrosis factor-alpha and matrix metalloproteinase expres-
with primary human broblasts. This work was supported
sion. Circulation 1998;98:300307.
by grants from the Swiss National Research Foundation [21] Aikawa M, Voglic SJ, Sugiyama S et al. Dietary lipid lowering
reduces tissue factor expression in rabbit atheroma. Circulation
(grants 3200-054965.98/ 1 and 3200-065121.01/ 1) to FM;
1999;100:12151222.
(3234-066311.01/ 1 and 3100-067777.02) to BRK; and
[22] Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial
(32-510069.97) to TFL. Additional support for this work
nitric oxide synthase by HMG CoA reductase inhibitors. Circulation
was obtained from the Leenaards Foundation (to BRK and
1998;97:11291135.
FM), the Swiss Heart Foundation of Cardiology and the [23] Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen
MJ. Dened daily doses in relation to hypolipidaemic efcacy of
Adumed Foundation (to CMM).
lovastatin, pravastatin, and simvastatin. Lancet 1994;343:1554
1555.
[24] Diomede L, Albani D, Sottocorno M et al. In vivo anti-inammatory
References
effect of statins is mediated by nonsterol mevalonate products.
Arterioscler Thromb Vasc Biol 2001;21:13271332.
[25] Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase
[1] Maron DJ, Fazio S, Linton MF. Current perspectives on statins.
inhibitors. Trends Cardiovasc Med 2000;10:143148.
Circulation 2000;101:207213.
[26] Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart [2] LaRosa JC. Statins and risk of coronary heart disease. J Am Med
JC, Najib-Fruchart J, Glineur C, Staels B. Statin-induced inhibition Assoc 2000;283:29352936.
of the Rho-signaling pathway activates PPARalpha and induces [3] Vaughan CJ, Gotto Jr. AM, Basson CT. The evolving role of statins
HDL apoA-I. J Clin Invest 2001;107:14231432. in the management of atherosclerosis. J Am Coll Cardiol
[27] Sparrow CP, Burton CA, Hernandez M et al. Simvastatin has 2000;35:110.
anti-inammatory and antiatherosclerotic activities independent of [4] Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-
plasma cholesterol lowering. Arterioscler Thromb Vasc Biol methylglutaryl coenzyme A reductase inhibitors. Arterioscler
2001;21:115121. Thromb Vasc Biol 2001;21:17121719.
[28] Wagner AH, Gebauer M, Gudenzorph B, Hecker M. 3-Hydroxy-3- [5] Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly
methylglutaryl coenzyme A reductase-independent inhibition of recognized type of immunomodulator. Nat Med 2000;6:13991402.
CD40 expression by atorvastatin in human endothelial cells. Ar- [6] Libby P, Ridker PM, Maseri A. Inammation and atherosclerosis.
terioscler Thromb Vasc Biol 2002;22:17841789. Circulation 2002;105:11351143.
[29] Schonbeck U, Gerdes N, Varo N et al. Oxidized low-density [7] Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell
lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A 2001;104:503516.
reductase inhibitors limit CD40 and CD40L expression in human [8] Schonbeck U, Libby P. The CD40/ CD154 receptor / ligand DYAD.
vascular cells. Circulation 2002;106:28882893. Cell Mol Life Sci 2001;58:443.
[30] Youssef S, Stuve O, Patarroyo JC et al. The HMG-CoA inhibitor, [9] Lutgens E, Daemen MJ. CD40CD40L interactions in atherosclero-
atorvastatin, promotes a Th2 bias and reverses paralysis in central sis. Trends Cardiovasc Med 2002;12:2732.
nervous system autoimmune disease. Nature 2002;420:7884. [10] Garlichs CD, John S, Schmeisser A et al. Upregulation of CD40 and
[31] Leung BP, Satta N, Crilly A et al. A novel anti-inammatory role for CD40 ligand (CD154) in patients with moderate hypercholes-
simvastatin in inammatory arthritis. J Immunol 2003;170:1524 terolemia. Circulation 2001;104:23952400.
1530. [11] Cipollone F, Mezzetti A, Porreca E et al. Association between
[32] Luster AD. Chemokineschemotactic cytokines that mediate in- enhanced soluble CD40L and prothrombotic state in hypercholes-
ammation. N Engl J Med 1998;338:436445. terolemia. Effects of statin therapy. Circulation 2002;106:399402.
[33] Mach F. The role of chemokines in atherosclerosis. Curr Atheroscler [12] Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P.
Rep 2001;3:243251. Reduction of atherosclerosis in mice by inhibition of CD40 sig-
[34] Lu B, Rutledge BJ, Gu L et al. Abnormalities in monocyte nalling. Nature 1998;394:200203.
recruitment and cytokine expression in monocyte chemoattractant [13] Lutgens E, Gorelik L, Daemen MJ et al. Requirement for CD154 in
protein 1-decient mice. J Exp Med 1998;187:601608. the progression of atherosclerosis. Nat Med 1999;5:13131316.
[35] Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoat- [14] Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune
tractant protein-1 reduces atherosclerosis in low density lipoprotein regulation by CD40 and its ligand GP39. Annu Rev Immunol
receptor-decient mice. Mol Cell 1998;2:275281. 1996;14:591617.
[15] Schonbeck U, Mach F, Libby P. CD154 (CD40 ligand). Int J [36] Crisby M, Nordin-Fredriksson G, Shah PK et al. Pravastatin
Biochem Cell Biol 2000;32:687693. treatment increases collagen content and decreases lipid content,
[16] Blum CB. Comparison of properties of four inhibitors of 3-hydroxy- inammation, metalloproteinases, and cell death in human carotid
3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73:3D plaques: implications for plaque stabilization. Circulation
11D. 2001;103:926933.
[17] Mazzei GJ, Edgerton MD, Losberger C et al. Recombinant soluble [37] De Caterina R, Libby P, Peng HB et al. Nitric oxide decreases
trimeric CD40 ligand is biologically active. J Biol Chem cytokine-induced endothelial activation. Nitric oxide selectively
1995;270:70257028. reduces endothelial expression of adhesion molecules and proinam-
[18] Mach F, Schonbeck U, Sukhova GK et al. Functional CD40 ligand matory cytokines. J Clin Invest 1995;96:6068.
b
y
g
u
e
s
t
o
n
A
p
r
i
l
2
5
,
2
0
1
4
h
t
t
p
:
/
/
c
a
r
d
i
o
v
a
s
c
r
e
s
.
o
x
f
o
r
d
j
o
u
r
n
a
l
s
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
f
r
o
m
766 F. Mulhaupt et al. / Cardiovascular Research 59 (2003) 755766
[38] Kwak BR, Myit S, Mulhaupt F et al. PPARgamma but not [41] Shimizu K, Schonbeck U, Mach F, Libby P, Mitchell RN. Host
PPARalpha ligands are potent repressors of major histocompatibility CD40 ligand deciency induces long-term allograft survival and
complex class II induction in atheroma-associated cells. Circ Res donor-specic tolerance in mouse cardiac transplantation but does
2002;90:356362. not prevent graft arteriosclerosis. J Immunol 2000;165:35063518.
[39] Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin [42] Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance
on outcomes after cardiac transplantation. N Engl J Med of skin and cardiac allografts after blocking CD40 and CD28
1995;333:621627. pathways. Nature 1996;381:434438.
[40] Wenke K, Meiser B, Thiery J et al. Simvastatin reduces graft vessel
disease and mortality after heart transplantation-a four year random-
ized trial. Circulation 1997;96:13981402.
b
y
g
u
e
s
t
o
n
A
p
r
i
l
2
5
,
2
0
1
4
h
t
t
p
:
/
/
c
a
r
d
i
o
v
a
s
c
r
e
s
.
o
x
f
o
r
d
j
o
u
r
n
a
l
s
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
f
r
o
m